Literature DB >> 20446882

Do candidate genes discriminate patients with an autism spectrum disorder from those with attention deficit/hyperactivity disorder and is there an effect of lifetime substance use disorders?

Bram Sizoo1, Wim van den Brink, Barbara Franke, Alejandro Arias Vasquez, Patricia van Wijngaarden-Cremers, Rutger Jan van der Gaag.   

Abstract

OBJECTIVE: Autism spectrum disorder (ASD) and attention deficit/hyperactivity disorder (ADHD) are developmental disorders that overlap in a number of domains, sometimes complicating clinical distinction between both disorders. Although there is some evidence for a genetic overlap, there are no reports on genes that could differentiate between ASD and ADHD. Furthermore, it is not known whether this genetic overlap is influenced by co-morbid substance use disorders (SUD).
METHODS: A total of 110 adult patients with ASD (n=61) or ADHD (n=49) with or without a lifetime history of SUD participated in a study in which we genotyped polymorphisms in five known candidate genes for (one of) the disorders, i.e. the 5HTTLPR in SLC6A4/5-HTT, rs1800497 (TaqIA C>T) in DRD2, rs7794745 in CNTNAP2, rs1843809 in TPH2, and rs6565113 in CDH13. Genotyping was by Taqman-based analysis or by simple sequence length analysis, where appropriate.
RESULTS: ASD could be differentiated from ADHD with nominal statistical significance by the 5HTTLPR, and the polymorphisms in TPH2 and CNTNAP2. The results were independent of lifetime SUD status.
CONCLUSIONS: Serotonergic genes could prove to play an important role in differentiating between ASD and ADHD, but the results of this exploratory study need replication.

Entities:  

Mesh:

Year:  2010        PMID: 20446882     DOI: 10.3109/15622975.2010.480985

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  6 in total

1.  Genetic background of extreme violent behavior.

Authors:  J Tiihonen; M-R Rautiainen; H M Ollila; E Repo-Tiihonen; M Virkkunen; A Palotie; O Pietiläinen; K Kristiansson; M Joukamaa; H Lauerma; J Saarela; S Tyni; H Vartiainen; J Paananen; D Goldman; T Paunio
Journal:  Mol Psychiatry       Date:  2014-10-28       Impact factor: 15.992

2.  Synaptic abnormalities and cytoplasmic glutamate receptor aggregates in contactin associated protein-like 2/Caspr2 knockout neurons.

Authors:  Olga Varea; Maria Dolores Martin-de-Saavedra; Katherine J Kopeikina; Britta Schürmann; Hunter J Fleming; Jessica M Fawcett-Patel; Anthony Bach; Seil Jang; Elior Peles; Eunjoon Kim; Peter Penzes
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

3.  Allele-specific associations of 5-HTTLPR/rs25531 with ADHD and autism spectrum disorder.

Authors:  Kenneth D Gadow; Carla J DeVincent; Victoria I Siegal; Doreen M Olvet; Saniya Kibria; Sarah F Kirsch; Eli Hatchwell
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-10-31       Impact factor: 5.067

4.  CNTNAP2 gene in high functioning autism: no association according to family and meta-analysis approaches.

Authors:  Anna Maria Werling; Elise Bobrowski; Regina Taurines; Ronnie Gundelfinger; Marcel Romanos; Edna Grünblatt; Susanne Walitza
Journal:  J Neural Transm (Vienna)       Date:  2015-11-11       Impact factor: 3.575

Review 5.  The genetics of attention deficit/hyperactivity disorder in adults, a review.

Authors:  B Franke; S V Faraone; P Asherson; J Buitelaar; C H D Bau; J A Ramos-Quiroga; E Mick; E H Grevet; S Johansson; J Haavik; K-P Lesch; B Cormand; A Reif
Journal:  Mol Psychiatry       Date:  2011-11-22       Impact factor: 15.992

6.  Interaction effect between handedness and CNTNAP2 polymorphism (rs7794745 genotype) on voice-specific frontotemporal activity in healthy individuals: an fMRI study.

Authors:  Michihiko Koeda; Atsushi Watanabe; Kumiko Tsuda; Miwako Matsumoto; Yumiko Ikeda; Woochan Kim; Amane Tateno; Banyar Than Naing; Hiroyuki Karibe; Takashi Shimada; Hidenori Suzuki; Masato Matsuura; Yoshiro Okubo
Journal:  Front Behav Neurosci       Date:  2015-04-20       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.